专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US6075032A Method of preventing proliferation of retinal pigment epithelium by retinoic acid receptor agonists 失效
标题翻译：视黄酸受体激动剂预防视网膜色素上皮细胞增生的方法
公开(公告)号：US6075032A
公开(公告)日：2000-06-13
申请号：US875665
申请日：1998-01-23
申请人： Peter A. Campochiaro , Larry A. Wheeler , Roshantha A. Chandraratna , Sunil Nagpal , Eugene De Juan, Jr.
发明人： Peter A. Campochiaro , Larry A. Wheeler , Roshantha A. Chandraratna , Sunil Nagpal , Eugene De Juan, Jr.
IPC分类号： A61K9/127 , A61K9/14 , A61K31/19 , A61K31/192 , A61K31/455 , A61K31/465 , A61K45/00 , A61K47/24 , A61P27/02 , A61P35/00 , A61K31/435 , A61K31/07
CPC分类号： A61K31/455 , A61K31/192 , Y10S514/912
摘要： Proliferation of retinal pigment epithelium following surgery or trauma or resulting in ocular diseases associated with choroidal neovascularization, such as age related macular degeneration and histoplasmosis syndrome, is prevented by contacting retinal pigment epithelium cells with a therapeutic amount of a retinoic acid receptor (RAR agonist, preferably one with specific activity for retinoic acid receptors. Preferably the RAR agonist is also a potent antagonist of AP1-dependent gene expression. Alternatively, the proliferation of retinal pigment epithelium is ameliorated with a therapeutic amount of an AP-1 antagonist, alone or in combination with an RAR agonist. The drug can be administered by bolus injection into the vitreous cavity using a dosage from about 50 to 150 .mu.g. Or by slow release from liposomes or an oil tamponade injected into the vitreous cavity. Formulations for preventing proliferation of retinal pigment epithelium are also provided.
摘要翻译： PCT No.PCT / US96 / 01505 Sec。 371日期1998年1月23日 102（e）日期1998年1月23日PCT提交1996年1月31日PCT公布。公开号WO96 / 23498 日期1996年8月8日通过使视网膜色素上皮细胞与治疗量的视黄酸接触来预防手术或创伤后视网膜色素上皮细胞增生或与脉络膜新生血管形成相关的眼部疾病，如年龄相关性黄斑变性和组织胞浆菌病综合征受体（RAR激动剂，优选具有对视黄酸受体具有比活性的激动剂），优选地，RAR激动剂也是AP1依赖性基因表达的有效拮抗剂，或者，用治疗量的AP-1改善视网膜色素上皮的增殖拮抗剂，单独或与RAR激动剂组合，药物可以通过使用约50至150μg的剂量通过快速注射进入玻璃体腔中，或通过从脂质体缓慢释放或注入玻璃体腔的油栓塞来施用。还提供了用于防止视网膜色素上皮细胞增殖的制剂。

2. 发明授权

US06573271B2 Method of preventing proliferation of retinal pigment epithelium by retinoic acid receptor agonists 失效
公开(公告)号：US06573271B2
公开(公告)日：2003-06-03
申请号：US09954686
申请日：2001-09-11
申请人： Peter A. Campochiaro , Larry A. Wheeler , Roshantha A. Chandraratna , Sunil Nagpal , Eugene De Juan, Jr.
发明人： Peter A. Campochiaro , Larry A. Wheeler , Roshantha A. Chandraratna , Sunil Nagpal , Eugene De Juan, Jr.
IPC分类号： A61K31435
CPC分类号： A61K31/455 , A61K31/192 , Y10S514/912
摘要： Proliferation of retinal pigment epithelium following surgery or trauma or resulting in ocular diseases associated with choroidal neovascularization, such as age related macular degeneration and histoplasmosis syndrome, is prevented by contacting retinal pigment epithelium cells with a therapeutic amount of a retinoic acid receptor (RAR agonist, preferably one with specific activity for retinoic acid receptors. Preferably the RAR agonist is also a potent antagonist of AP1-dependent gene expression. Alternatively, the proliferation of retinal pigment epithelium is ameliorated with a therapeutic amount of an AP-1 antagonist, alone or in combination with an RAR agonist. The drug can be administered by bolus injection into the vitreous cavity using a dosage from about 50 to 150 &mgr;g. Or by slow release from liposomes or an oil tamponade injected into the vitreous cavity. Formulations for preventing proliferation of retinal pigment epithelium are also provided.

3. 发明授权

US06372753B1 Method of preventing proliferation of retinal pigment epithelium by retinoic acid receptor agonists 失效
标题翻译：视黄酸受体激动剂预防视网膜色素上皮细胞增生的方法
公开(公告)号：US06372753B1
公开(公告)日：2002-04-16
申请号：US09536221
申请日：2000-03-27
申请人： Peter A. Campochiaro , Larry A. Wheeler , Roshantha A. Chandraratna , Sunil Nagpal , Eugene De Juan, Jr.
发明人： Peter A. Campochiaro , Larry A. Wheeler , Roshantha A. Chandraratna , Sunil Nagpal , Eugene De Juan, Jr.
IPC分类号： A61K31435
CPC分类号： A61K31/455 , A61K31/192 , Y10S514/912
摘要： Proliferation of retinal pigment epithelium following surgery or trauma or resulting in ocular diseases associated with choroidal neovascularization, such as age related macular degeneration and histoplasmosis syndrome, is prevented by contacting retinal pigment epithelium cells with a therapeutic amount of a retinoic acid receptor (RAR agonist, preferably one with specific activity for retinoic acid receptors. Preferably the RAR agonist is also a potent antagonist of AP1-dependent gene expression. Alternatively, the proliferation of retinal pigment epithelium is ameliorated with a therapeutic amount of an AP-1 antagonist, alone or in combination with an RAR agonist. The drug can be administered by bolus injection into the vitreous cavity using a dosage from about 50 to 150 &mgr;g. Or by slow release from liposomes or an oil tamponade injected into the vitreous cavity. Formulations for preventing proliferation of retinal pigment epithelium are also provided.
摘要翻译：通过使视网膜色素上皮细胞与治疗量的视黄酸受体（RAR激动剂，血管内皮细胞生长因子受体）接触，可防止手术或外伤后视网膜色素上皮细胞增生，或导致与脉络膜新生血管形成相关的眼部疾病，如年龄相关性黄斑变性和组织胞浆菌病综合征优选地，具有比较活性的视黄酸受体，优选地，RAR激动剂也是AP1依赖性基因表达的有效拮抗剂，或者，视网膜色素上皮的增殖用治疗量的AP-1拮抗剂单独或在与RAR激动剂组合，药物可以通过使用约50至150杯的剂量通过快速注射进入玻璃体腔，或通过从脂质体缓慢释放或注射到玻璃体腔中的油脂填充剂来制备。用于防止视网膜增殖的制剂还提供了色素上皮。

4. 发明授权

US08814819B2 Glaucoma treatment device 有权
公开(公告)号：US08814819B2
公开(公告)日：2014-08-26
申请号：US12970482
申请日：2010-12-16
申请人： Eugene De Juan, Jr. , Stephen Boyd , Mark E. Deem , Hanson S. Gifford, III , Dan Rosenman
发明人： Eugene De Juan, Jr. , Stephen Boyd , Mark E. Deem , Hanson S. Gifford, III , Dan Rosenman
IPC分类号： A61F9/00 , A61F9/007 , A61K9/00 , A61M27/00
CPC分类号： A61F9/00781 , A61B34/70 , A61B90/00 , A61F2/14 , A61F2/142 , A61F9/0008 , A61F9/0017 , A61F9/007 , A61F9/00736 , A61F9/0133 , A61F11/00 , A61F2250/0001 , A61F2250/0096 , A61F2250/0097 , A61K9/0051 , A61M27/002 , A61M2202/04 , A61M2210/0612
摘要： Methods and devices are adapted for implanting into the eye. An incision is formed in the cornea of the eye and a shunt is inserted through the incision into the anterior chamber of the eye. The shunt includes a fluid passageway. The shunt is passed along a pathway from the anterior chamber through the scleral spur of the eye into the suprachoroidal space and positioned in a first position such that a first portion of the fluid passageway communicates with the anterior chamber and a second portion of the fluid passageway communicates with the suprachoroidal space to provide a fluid passageway between the suprachoroidal space and the anterior chamber.

5. 发明授权

US08801649B2 Glaucoma treatment device 有权
标题翻译：青光眼治疗装置
公开(公告)号：US08801649B2
公开(公告)日：2014-08-12
申请号：US12898593
申请日：2010-10-05
申请人： Eugene De Juan, Jr. , Stephen Boyd , Mark E. Deem , Hanson S. Gifford, III , Dan Rosenman
发明人： Eugene De Juan, Jr. , Stephen Boyd , Mark E. Deem , Hanson S. Gifford, III , Dan Rosenman
IPC分类号： A61M27/00 , A61B17/32 , A61M5/00 , A61F9/007 , A61F11/00 , A61B19/00 , A61F2/14
CPC分类号： A61F9/00781 , A61B34/70 , A61B90/00 , A61F2/14 , A61F2/142 , A61F9/0008 , A61F9/0017 , A61F9/007 , A61F9/00736 , A61F9/0133 , A61F11/00 , A61F2250/0001 , A61F2250/0096 , A61F2250/0097 , A61K9/0051 , A61M27/002 , A61M2202/04 , A61M2210/0612
摘要： Methods and devices are adapted for implanting into the eye. An incision is formed in the cornea of the eye and a shunt is inserted through the incision into the anterior chamber of the eye. The shunt includes a fluid passageway. The shunt is passed along a pathway from the anterior chamber through the scleral spur of the eye into the suprachoroidal space and positioned in a first position such that a first portion of the fluid passageway communicates with the anterior chamber and a second portion of the fluid passageway communicates with the suprachoroidal space to provide a fluid passageway between the suprachoroidal space and the anterior chamber.
摘要翻译：方法和装置适于植入眼睛。在眼睛的角膜中形成切口，并且通过切口将分路插入眼睛的前房。分流器包括流体通道。所述分流器沿着从所述前房通过所述眼睛的巩膜刺入所述脉管外空间的路径通过并且定位在第一位置，使得所述流体通道的第一部分与所述前房连通，并且所述流体通道的第二部分与脉管外空间连通，以在脉络膜上空间和前房之间提供流体通道。

6. 发明授权

US08734378B2 Glaucoma treatment device 有权
公开(公告)号：US08734378B2
公开(公告)日：2014-05-27
申请号：US12561680
申请日：2009-09-17
申请人： Eugene De Juan, Jr. , Stephen Boyd , Mark E. Deem , Hanson S. Gifford, III , Dan Rosenman
发明人： Eugene De Juan, Jr. , Stephen Boyd , Mark E. Deem , Hanson S. Gifford, III , Dan Rosenman
IPC分类号： A61F11/00 , A61F9/00 , A61F9/007 , A61F9/013 , A61M27/00
CPC分类号： A61F9/00781 , A61B34/70 , A61B90/00 , A61F2/14 , A61F2/142 , A61F9/0008 , A61F9/0017 , A61F9/007 , A61F9/00736 , A61F9/0133 , A61F11/00 , A61F2250/0001 , A61F2250/0096 , A61F2250/0097 , A61K9/0051 , A61M27/002 , A61M2202/04 , A61M2210/0612
摘要： Methods and devices are adapted for implanting into the eye. An incision is formed in the cornea of the eye and a shunt is inserted through the incision into the anterior chamber of the eye. The shunt includes a fluid passageway. The shunt is passed along a pathway from the anterior chamber through the scleral spur of the eye into the suprachoroidal space and positioned in a first position such that a first portion of the fluid passageway communicates with the anterior chamber and a second portion of the fluid passageway communicates with the suprachoroidal space to provide a fluid passageway between the suprachoroidal space and the anterior chamber.

7. 发明授权

US08628792B2 Drug cores for sustained release of therapeutic agents 有权
标题翻译：用于持续释放治疗剂的药物核心
公开(公告)号：US08628792B2
公开(公告)日：2014-01-14
申请号：US13367823
申请日：2012-02-07
申请人： Deepank Utkhede , Robert W. Shimizu , Rachna Jain , Stephen Boyd , Hanson S. Gifford , Eugene De Juan, Jr. , Cary J. Reich
发明人： Deepank Utkhede , Robert W. Shimizu , Rachna Jain , Stephen Boyd , Hanson S. Gifford , Eugene De Juan, Jr. , Cary J. Reich
IPC分类号： A61F2/00 , B28B11/12
CPC分类号： A61K9/0051 , A61F9/0017 , A61F9/00772 , A61F2230/0069 , A61F2250/0067 , A61K31/5575 , A61K47/34 , A61L27/54 , A61L2300/41 , A61L2300/602 , A61L2300/802 , Y02A50/395
摘要： A solid drug core insert can be manufactured by injecting a liquid mixture comprising a therapeutic agent and a matrix precursor into a sheath body. The injection can be conducted at subambient temperatures. The mixture is cured to form a solid drug-matrix core. The therapeutic agent can be a liquid at about room temperature that forms a dispersion of droplets in the matrix material. A surface of the solid drug core is exposed, for example by cutting the tube, and the exposed surface of the solid drug core releases therapeutic quantities of the therapeutic agent when implanted into the patient. In some embodiments, the insert body inhibits release of the therapeutic agent, for example with a material substantially impermeable to the therapeutic agent, such that the therapeutic quantities are released through the exposed surface, thereby avoiding release of the therapeutic agent to non-target tissues.
摘要翻译：可以通过将包含治疗剂和基质前体的液体混合物注入鞘体来制造固体药物核心插入物。注射可以在低于环境温度下进行。将混合物固化以形成固体药物基质核心。治疗剂可以是在约室温下的液体，其形成液滴在基质材料中的分散体。固体药物核心的表面例如通过切割管而暴露，并且固体药物核心的暴露表面在植入患者体内释放治疗剂量。在一些实施方案中，插入体抑制治疗剂的释放，例如具有对治疗剂基本上不可渗透的材料，使得治疗量通过暴露表面释放，从而避免将治疗剂释放到非靶组织。

8. 发明授权

US08721656B2 Glaucoma treatment device 有权
公开(公告)号：US08721656B2
公开(公告)日：2014-05-13
申请号：US11615810
申请日：2006-12-22
申请人： Eugene De Juan, Jr. , Stephen Boyd , Mark E. Deem , Hanson S. Gifford, III , Dan Rosenman
发明人： Eugene De Juan, Jr. , Stephen Boyd , Mark E. Deem , Hanson S. Gifford, III , Dan Rosenman
IPC分类号： A61F11/00 , A61F9/00 , A61F9/007 , A61F9/013 , A61M27/00
CPC分类号： A61F9/00781 , A61B34/70 , A61B90/00 , A61F2/14 , A61F2/142 , A61F9/0008 , A61F9/0017 , A61F9/007 , A61F9/00736 , A61F9/0133 , A61F11/00 , A61F2250/0001 , A61F2250/0096 , A61F2250/0097 , A61K9/0051 , A61M27/002 , A61M2202/04 , A61M2210/0612
摘要： Methods and devices are adapted for implanting into the eye. An incision is formed in the cornea of the eye and a shunt is inserted through the incision into the anterior chamber of the eye. The shunt includes a fluid passageway. The shunt is passed along a pathway from the anterior chamber through the scleral spur of the eye into the suprachoroidal space and positioned in a first position such that a first portion of the fluid passageway communicates with the anterior chamber and a second portion of the fluid passageway communicates with the suprachoroidal space to provide a fluid passageway between the suprachoroidal space and the anterior chamber.

9. 发明授权

US08672870B2 Ocular implant with hydrogel expansion capabilities 有权
标题翻译：眼部植入物具有水凝胶扩张能力
公开(公告)号：US08672870B2
公开(公告)日：2014-03-18
申请号：US12175294
申请日：2008-07-17
申请人： Tom Silvestrini , Eugene De Juan, Jr. , Dan Rosenman
发明人： Tom Silvestrini , Eugene De Juan, Jr. , Dan Rosenman
IPC分类号： A61M5/00 , A61M35/00
CPC分类号： A61F9/00781 , A61F2210/0061 , A61F2250/0087
摘要： An ocular implant includes an elongate member having an internal lumen forming a flow pathway that provides a fluid pathway between the anterior chamber and the suprachoroidal space of the eye. The implant includes a hydrogel member attached to the elongate member, wherein the hydrogel member is adapted to expand upon implantation of the elongate member in the eye. An attachment attaches the hydrogel member to the elongate member.
摘要翻译：眼部植入物包括细长构件，其具有形成流动路径的内部内腔，所述流动路径在眼睛的前房和脉管外空间之间提供流体通路。所述植入物包括连接到所述细长构件的水凝胶构件，其中所述水凝胶构件适于在细长构件植入眼中时扩张。附件将水凝胶构件附接到细长构件。

10. 发明授权

US08414646B2 Intraocular, accommodating lens and methods of use 有权
公开(公告)号：US08414646B2
公开(公告)日：2013-04-09
申请号：US12341799
申请日：2008-12-22
申请人： Eugene De Juan, Jr. , Stephen Boyd , Hanson Gifford , Cary Reich
发明人： Eugene De Juan, Jr. , Stephen Boyd , Hanson Gifford , Cary Reich
IPC分类号： A61F2/16
CPC分类号： A61F2/1694 , A61F2/1635 , A61F2/1648 , A61F2002/1682 , A61F2210/0019
摘要： An intraocular lens is adapted for insertion into a capsular bag having a zonular contact region. The intraocular lens comprises a shape changing optical element and an accommodating element comprising at least one force transmitting element and a plurality of spaced apart contacting elements each adapted to contact a portion of the zonular contact region and transmit compressive displacement radially inward at an oblique angle to the optical element and configured to cooperate with at least one of the ciliary muscle of the mammalian eye, the zonules of the mammalian eye and the vitreous pressure in the eye to effect an accommodating shape and a disaccommodating shape change to the optical element.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式